ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, ...
The Manila Times

BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health

BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases.
The Manila Times

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease ...